New hope: Alzheimer's trial targets tau tangles to slow memory loss
NCT ID NCT06957418
First seen Jun 27, 2026 · Last updated Jul 10, 2026 · Updated 2 times
Summary
This study tests whether drugs that target tau protein, alone or with donanemab, can reduce tau buildup and slow memory decline in people aged 50-80 with early Alzheimer's. Participants will receive treatment for 30 months and undergo brain scans and cognitive tests. The goal is to find a safe combination that slows disease progression.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALZHEIMER DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of California, San Francisco
RECRUITINGSan Francisco, California, 94158, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a simple questionnaire empower dementia caregivers after hospital stays?
- Could your heart hold the key to Alzheimer's prevention?
- Can a nudge in your chart unlock Life-Saving genetic clues?
- Can a Voice-Based app map healthy brain aging across 80 years?
- Can MRI reveal the Brain's response to deep brain stimulation?
- Can brain scans and gut bacteria reveal Alzheimer's secrets?